About 1,371,031 results (3,927 milliseconds)

WO2021193984A2 - Qd dosing of gip receptor agonist peptide ...

https://patents.google.com/patent/WO2021193984A2/en
emesis for example, nausea and/or vomiting. Nausea can be measured in ways known to the art, such as through the use of a visual analog scale (VAS). VAS ...

WO2018181864A1 - Gip receptor activating peptide - Google Patents

https://patents.google.com/patent/WO2018181864A1/en
... nausea and vomiting. the vomiting or nausea also includes imminent ... [21] The medicament according to [19], which is a suppressant for vomiting or nausea.

CN111918655A - Methods of treating diabetic subjects with chronic ...

https://patents.google.com/patent/CN111918655A/en
Prediabetes is a predisposing stage prior to diabetes, in which not all symptoms ... Nausea and vomiting symptoms claims,description 2 0.000. dyspepsia ...

US20230278991A1 - Glp-1r agonists and uses thereof - Google ...

https://patents.google.com/patent/US20230278991A1/ru
Obesity is a chronic disease that is highly prevalent in modern society and is ... pre-diabetes, NASH, and cardiovascular disease. Structural Formula (I) ...

WO2021030613A1 - Rnai constructs for inhibiting slc30a8 ...

https://patents.google.com/patent/WO2021030613A1/en
[0006] The present invention is based, in part, on the design and generation of RNAi constructs that target the SLC30A8 gene and reduce expression of SLC30A8 in ...

US20220024901A1 - Glp-1r agonists and uses thereof - Google ...

https://patents.google.com/patent/US20220024901A1
Legal status (The legal status is an assumption and is not a legal conclusion. ... prediabetes syndrome Diseases 0.000 claims abstract description 13 ...

US20210290732A1 - GLP-1R and GCGR Agonists, Formulations ...

https://patents.google.com/patent/US20210290732A1/en
... prediabetes syndrome Diseases 0.000 description 1; 238000002203 ... the adverse events can include nausea, vomiting, diarrhea, abdominal pain and ...

WO2020103815A1 - Glp-1r agonists and uses thereof - Google ...

https://patents.google.com/patent/WO2020103815A1/en
Priority date (The priority date is an assumption and is not a legal conclusion. ... prediabetes syndrome Diseases 0.000 claims abstract description 15 ...

US20200316066A1 - Killing senescent cells and treating ...

https://patents.google.com/patent/US20200316066A1/en
Persistent low grade inflammation in the lower respiratory tract can cause proteolytic and ... prediabetes, and/or gestational diabetes. [0185]. The ...

EP4110800A1 - Peptides as selective gip receptor agonists ...

https://patents.google.com/patent/EP4110800A1/en
... and does not activate the glucagon receptor ... The vomiting also includes acute vomiting, protracted vomiting, and anticipatory vomiting.

EA012071B1 - Y4 selective receptor agonists for therapeutic ...

https://patents.google.com/patent/EA012071B1/en
... does not cause vomiting. Large doses of the combined Υ2-Υ4 peptide agonist with similar PΥΥsh νίΙΐΌ activity to Υ2 receptors can be administered to animals ...

WO2010092123A1 - Sglt-2 inhibitor for treating type 1 diabetes ...

https://patents.google.com/patent/WO2010092123A1/en20
the scientific and medical basis for identifying prediabetes as a serious health threat is ... Typical symptoms of water intoxication include nausea, vomiting, ...

US20190385725A1 - Methods for lowering blood sugar with a ...

https://patents.google.com/patent/US20190385725A1/en
... and nearly 35% of all adults in the U.S. had prediabetes. Centers for ... is drinking less than before, vomiting, diarrhea, and/or dehydration. [0212].

WO2010132562A2 - Transdermal delivery of metformin - Google ...

https://patents.google.com/patent/WO2010132562A2/en
... nausea, vomiting, abdominal discomfort and diarrhea. Up to 20% of patients taking oral metformin will experience one of these side effects. The effects are dose ...

WO2020207474A1 - Glp-1r agonists and uses thereof - Google ...

https://patents.google.com/patent/WO2020207474A1/en
... prediabetes syndrome Diseases 0.000 claims abstract description 10 ... Obesity is a chronic disease that is highly prevalent in modern society and is ...

JP5543110B2 - Potassium ATP channel opener salt and use thereof ...

https://patents.google.com/patent/JP5543110B2/en
... is not a KATP channel opener. In certain embodiments, the other pharmaceutically active agent is obesity, pre-diabetes, diabetes, hypertension, depression ...

US9458118B2 - Sodium channel modulators for the treatment of ...

https://patents.google.com/patent/US9458118B2/en
... vomiting, shortness of breath, dry mouth, weakness, confusion ... In one embodiment, the prediabetes or diabetes is caused by or accompanied by obesity.

GB2496761A - Tetrahydrocannabivarin for use in treating diabetes ...

https://patents.google.com/patent/GB2496761
It has been suggested that lifestyle-intervention and treating metabolic manifestations of this pre-diabetic state can reduce the chance of progression to frank ...

EP1648878B9 - Piperidine compounds and pharmaceutical ...

https://patents.google.com/patent/EP1648878B9/en
... vomiting, dyskinesia, or depression in an animal comprising ... Ar 2 is and q is 1. Ar 1 is a pyridyl group; X is O; m is 0,; R 4 is -halo; Ar 2 ...